SCHEMBL13635444

SCHEMBL13635444

Cc1cccc(-n2cc(-c3ccc(Cl)cc3)ccc2=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 2/20 0.45
CYP1A2 P05177 1/20 0.45
BLM P54132 1/20 0.45
HSD17B10 Q99714 1/20 0.45
GRM1 Q13255 1/20 0.42
MAPT P10636 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HSP90AA1 P07900 1/20 0.41
MGLL Q99685 1/20 0.41
KMT2A Q03164 7/20 0.41
LMNA P02545 4/20 0.41
HTT P42858 4/20 0.41
MEN1 O00255 4/20 0.41
GAA P10253 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
NOD2 Q9HC29 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10059948 0.89 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL10059924 0.89 KDM4E (0.43) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL14883635 0.85 ALDH1A1 (0.45) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL13635449 0.82 ALDH1A1 (0.45) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL14883627 0.82 KDM4E (0.42) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL10059881 0.81 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL10059939 0.80 IDH1 (0.44) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL14883623 0.80 TNKS2 (0.47) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL14883516 0.80 ALDH1A1 (0.40) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL10059942 0.80 ALDH1A1 (0.40) ALDH1A1HPGDKDM4ECYP1A2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969347-B2 Compounds and methods for treating inflammatory and fibrotic disorders INTERMUNE, INC. 2015-03-03 US disclosed
US-20130102597-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2013-04-25 US disclosed
US-8304413-B2 Compounds and methods for treating inflammatory and fibrotic disorders INTERMUNE, INC. (US) 2012-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102597-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS MAP3K8, MAP3K1, MAP3K6 ALDH1A1 2054/4885HPGD 529/4885KDM4E 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.